GLP-1 Peptides for Weight Loss: The Complete Class Overview (Semaglutide to Retatrutide)

GLP-1 peptides are the reason weight management research reorganized itself around a single receptor family in under a decade. What started as a diabetes mechanism, a gut hormone that tells the pancreas to release insulin after a meal, became the basis for the largest mean weight-loss figures ever reported in controlled obesity trials. The story is not one compound; it is a ladder. Each new molecule added a receptor to the one before it, and the trial data climbed in step with the mechanism. ^[5]

This guide is the map of that ladder: what a GLP-1 peptide is, how the incretin and glucagon mechanisms combine, what each trial actually reported, where the emerging compounds fit, and what a research buyer needs to know before choosing and sourcing one. It is written for research and educational purposes. Everything here reports what the published clinical literature describes; none of it is medical advice, and every compound referenced is a research compound, not approved for human use in that context.

The GLP-1 peptide class at a glance

Read the table as a progression, not a leaderboard. The three lead compounds sit on a clean mechanism ladder, one receptor added at a time, and the trial figures climb with them. Survodutide takes a different second receptor (glucagon instead of GIP), which is why it belongs on a parallel branch rather than further up the same ladder. Cagrilintide is a different mechanism altogether, an amylin analog rather than an incretin, which is why it is usually studied as a combination partner rather than a standalone competitor to the GLP-1 monotherapies.

What are GLP-1 peptides?

A GLP-1 peptide is an engineered version of, or a molecule built around, glucagon-like peptide-1, a gut hormone released after eating that tells the pancreas to release insulin, slows how fast food leaves the stomach, and signals satiety to the brain. Native GLP-1 lasts only a few minutes in circulation before an enzyme called DPP-4 breaks it down, which makes it useless as a once-weekly drug on its own. The entire GLP-1 peptide class exists because researchers found ways to keep a GLP-1-based molecule intact and circulating for days instead of minutes, primarily by resisting DPP-4 and binding the molecule to serum albumin, a long-lived blood protein. ^[6]

Once that engineering problem was solved, the next question became what else a similarly built molecule could do. GIP (glucose-dependent insulinotropic polypeptide) is a second incretin hormone that shares a family resemblance with GLP-1 at the receptor level, close enough that one engineered peptide can be shaped to activate both. Glucagon is not an incretin at all; on its own it raises blood glucose and mobilizes stored energy, but paired with strong GLP-1 and GIP coverage, its energy-expenditure contribution can be captured while the incretin arms offset the glycemic penalty. ^[5] That is the entire logic of the class: start with GLP-1, then add related receptors whose contributions complement rather than compete with it.

Is retatrutide, tirzepatide, or semaglutide "a GLP-1"?

This question comes up constantly because the terminology gets used loosely. Semaglutide is a pure single-receptor GLP-1 agonist, so calling it "a GLP-1" is precise. Tirzepatide activates both the GLP-1 and GIP receptors, so it is a GLP-1 receptor agonist and a GIP receptor agonist at once, more precisely described as a dual agonist. Retatrutide activates GLP-1, GIP, and glucagon receptors, so it is accurately described as a GLP-1 receptor agonist among other things, but the precise term is triple-hormone-receptor agonist. In everyday usage, "GLP-1 peptides" or "the GLP-1 class" refers to the whole family, single, dual, and triple agonists alike, because they all share the GLP-1 receptor as a common foundation. ^[5]

How the mechanism ladder works: from single to triple agonism

The single clearest way to understand this class is to walk up the ladder one receptor at a time, because each addition is a deliberate answer to what the previous compound left on the table.

GLP-1 is the foundation every compound in this guide shares. It reduces appetite, slows gastric emptying, and stimulates insulin release only when blood glucose is elevated, which is why the class as a whole carries a low intrinsic risk of driving glucose too low. GIP was, for years, considered a weaker target on its own, but tirzepatide's trial program showed that pairing it with GLP-1 amplifies the incretin effect rather than simply adding a second, independent one. ^[4] Glucagon is the more surprising addition: by itself it pushes blood glucose up, but combined with strong incretin coverage its energy-expenditure and lipid-mobilization contribution shows up as extra weight loss without the glycemic downside it would carry alone. ^[5] Amylin is a separate branch entirely, a pancreatic hormone that slows gastric emptying and promotes satiety through its own receptor, which is why cagrilintide is usually paired with a GLP-1 compound (as CagriSema) rather than deployed alone.

This pattern, more validated receptor coverage tracking with a larger mean trial figure, is not proof that each receptor contributes a fixed, additive increment (these are separate trials, with separate populations and durations). But it is the strongest available signal that the multi-receptor thesis is doing real mechanistic work. ^{[2] [3]}

The GLP-1 peptides list: a compound-by-compound rundown

With the mechanism ladder established, here is what each compound actually is, in the order it entered the field.

Semaglutide: the single-receptor reference point

Semaglutide activates the GLP-1 receptor alone. It is the most extensively studied compound in this class, with the STEP program (four pivotal weight-management trials) and the earlier SUSTAIN diabetes program behind it, plus years of post-marketing data under its approved brand names. STEP 1 reported 14.9% mean weight loss at 68 weeks on the 2.4 mg dose, the figure that established the modern GLP-1 weight-management category. ^[1] The complete trial-by-trial breakdown is in the complete semaglutide guide.

Tirzepatide: the dual-agonist upgrade

Tirzepatide adds the GIP receptor to the same GLP-1 foundation. SURMOUNT-1 reported 20.9% mean weight loss at 72 weeks on the 15 mg dose, and the SURPASS-2 head-to-head trial directly compared it against semaglutide in people with type 2 diabetes, where all three tirzepatide doses outperformed semaglutide 1 mg on both weight and glycemic control, the strongest single piece of evidence in the class that a second receptor adds real effect. ^{[2] [4]} The full SURMOUNT and SURPASS breakdown is in the complete tirzepatide guide.

Retatrutide: the triple-agonist frontier

Retatrutide adds the glucagon receptor on top of GLP-1 and GIP, making it the first engineered peptide to activate all three at once. Its Phase 2 obesity trial, published in the New England Journal of Medicine in 2023, reported 24.2% mean weight loss at 48 weeks on the 12 mg dose, without the weight curve clearly plateauing by study end, the largest mean reduction reported for a GLP-1-class compound to date. ^[3] The full mechanism, Phase 2 data, dosing, and sourcing are covered in the complete retatrutide guide.

Survodutide: the glucagon branch, taken differently

Survodutide takes a different second step than tirzepatide: instead of pairing GLP-1 with GIP, it pairs GLP-1 directly with glucagon, the same receptor retatrutide adds as its third arm, but here as the second. Reported topline Phase 2 obesity data described mean weight loss reaching approximately 18.7% at the highest studied dose over 46 weeks, a figure that would place it above semaglutide and in a similar range to tirzepatide on a cross-trial basis. ^[7] Its obesity program is earlier stage than the three lead compounds, with Phase 3 trials underway to confirm the signal at larger scale.

Cagrilintide and CagriSema: the amylin branch

Cagrilintide is not an incretin peptide at all; it is a long-acting analog of amylin, a hormone that slows gastric emptying and promotes satiety through its own dedicated receptor. Studied alone in a Phase 2 dose-finding trial, the 4.5 mg dose produced 10.8% mean weight loss at 26 weeks, a meaningful standalone effect but well below the lead GLP-1 compounds over a comparable window. ^[8] Its more closely watched role is as a combination partner: paired with semaglutide 2.4 mg as CagriSema, reported Phase 3 topline figures described mean weight loss around 20% at 68 weeks, a result that drew attention for landing below some analysts' pre-trial expectations. ^[9]

Efficacy tiers: how much weight loss do GLP-1 peptides produce

The single most-asked question in this space is how much weight each compound actually moves, and the honest answer requires naming the trial each figure comes from, since none of these are drawn from one shared study.

Two caveats matter as much as the numbers themselves. First, trial duration differs across rows, and none of these compounds' weight curves had clearly plateaued at their endpoints, so a shorter-duration figure (survodutide and cagrilintide's 26 to 46-week windows) is not directly comparable to a longer one (tirzepatide's 72 weeks). Second, trial populations differ: some enrolled people with type 2 diabetes, who historically show a smaller mean effect on GLP-1 therapy. The one figure in this table backed by a genuine head-to-head trial rather than a cross-trial comparison is the GIP contribution shown in SURPASS-2, where tirzepatide directly outperformed semaglutide in the same trial, at the same time, in the same population. ^[4]

Side effects across the GLP-1 class

Every compound on this ladder shares the same dominant side-effect pattern, and that consistency is itself informative: it means the effects are mechanism-driven rather than compound-specific quirks. Gastrointestinal effects, nausea, diarrhea, constipation, and reduced appetite, are the most commonly reported effects across semaglutide, tirzepatide, and retatrutide trials, all dose-dependent and concentrated during dose escalation, then easing once a stable dose is reached. ^{[1] [2] [3]}

The reason is direct rather than incidental: GLP-1 receptor activation slows gastric emptying, which is part of how the whole class suppresses appetite, and the same slowing produces nausea when exposure rises faster than the gut can adapt. That is why every compound's clinical program uses a stepwise titration schedule rather than starting at the target dose, and why the effects cluster during the ramp and fade at steady state. Retatrutide's trial data additionally reported a distinct skin-sensation effect (dysesthesia) at higher doses, a finding specific to that compound rather than shared across the class. ^[3] Full side-effect breakdowns, including incidence figures and management patterns reported in each compound's own trial program, live in the compound-specific guides linked throughout this post.

Because the mechanism is the same across the class, the tolerability lesson is also the same: a gradual titration, not a rushed one, is what keeps GI effects manageable while plasma levels climb toward steady state, typically around 4 to 5 weeks in for the once-weekly compounds here. Reading the first month as a verdict on the compound is the most common misread in this space.

GLP-1 peptides vs each other: how to choose

Choosing among semaglutide, tirzepatide, and retatrutide is less about which is "better" in the abstract and more about what a specific research question calls for.

This is not a hierarchy where retatrutide simply replaces the others. Semaglutide has the most complete safety and pharmacology picture; tirzepatide has the strongest direct evidence of outperforming a single-receptor compound; retatrutide has the largest reported effect but the shortest track record. A protocol built around comparing mechanisms, not chasing the newest compound by default, makes the most of that spread. For direct comparisons, see semaglutide, tirzepatide, and retatrutide.

Dosing cadence across the class: why they are all once weekly

Every lead compound in this guide is dosed once weekly by subcutaneous injection, and that shared cadence is not a coincidence; it follows from the same engineering choice applied to each molecule.

Native incretin hormones last only minutes in circulation. Every compound in this class reaches days-long half-lives through the same two engineering moves: resisting the DPP-4 enzyme that would otherwise clip the peptide apart, and binding to serum albumin, a long-lived blood protein that keeps the molecule circulating instead of being cleared quickly by the kidneys. ^[6] That shared engineering approach is why a semaglutide, tirzepatide, or retatrutide protocol all follow the same basic shape: stepwise titration over weeks, a steady-state window around a month in, and once-weekly maintenance dosing. The exact dose steps and durations for each compound are detailed in its complete guide.

Timeline: how long before GLP-1 peptides start working

Because every compound in this class shares the same pharmacokinetic engineering, they also share a similar week-by-week shape, even though the trial endpoints differ (48 weeks for retatrutide's Phase 2, 68 to 72 weeks for semaglutide and tirzepatide's pivotal trials).

The single most common mistake across the entire class is judging a protocol during the first month, while the dose is still low and plasma levels have not yet reached steady state. Every one of the three lead compounds' pivotal trials measured its headline figure at or beyond the multi-month mark for exactly this reason: the early weeks are known, structurally, to understate the eventual effect.

Is it legal? What "research use only" means for GLP-1 peptides

Semaglutide and tirzepatide are legal, FDA-approved molecules under their respective brand names (Ozempic, Wegovy, Mounjaro, and Zepbound). Retatrutide, survodutide, and cagrilintide are investigational and not approved for human use anywhere in the world at the time of writing. What "research use only" refers to, across all of them, is the sourcing channel: research-grade material sold outside the approved pharmacy supply chain, intended for laboratory and pre-clinical study rather than human administration, and labeled accordingly. That distinction, between a molecule's regulatory status and a specific product's approved indication and intended use, is what most searches on this topic are actually asking about.

Common myths and misconceptions about the GLP-1 class

A handful of claims recur across every compound in this family, and they are worth addressing once at the class level rather than compound by compound.

Where to buy GLP-1 peptides: what to look for when sourcing

Because retatrutide, survodutide, and cagrilintide are investigational, and research-grade semaglutide and tirzepatide are also commonly sourced outside the approved pharmacy channel for laboratory study, sourcing quality is the decisive variable across the entire class. The most important thing to verify is a batch-matched certificate of analysis tied to a specific lot: mass by HPLC, identity by mass spectrometry, a measured purity figure, and a characterized impurity profile, ideally confirmed by an independent third-party lab rather than the manufacturer's own numbers alone.

Our full standard for evaluating a supplier is documented in how we vet a new manufacturer. Modern Bio's semaglutide, tirzepatide, and retatrutide each ship with a batch-matched COA on every vial. Reconstitution follows the same procedure across the class: lyophilized powder reconstituted with bacteriostatic water, added slowly down the vial wall, swirled rather than shaken, and stored refrigerated with the date labeled. The complete procedure is in how to reconstitute peptides with bacteriostatic water.

Common mistakes across GLP-1 research protocols

• Reading the first month as the verdict. Every compound in this class needs roughly 4 to 5 weeks to reach steady state; early readings systematically understate the eventual effect.
• Escalating faster than the studied titration schedule. Each compound's clinical program used a stepwise ramp specifically to manage GI tolerability; compressing it is the most common reason a protocol is abandoned mid-titration.
• Comparing cross-trial figures as if they were head-to-head. Only a handful of comparisons in this class (SURPASS-2 and SURMOUNT-5 among them) come from genuine head-to-head trials; most of the numbers in this guide are drawn from separate studies with different populations and durations. ^[4]
• Sloppy reconstitution. Foaming, shaking, and freeze-thaw cycles degrade the peptide before it reaches the model system, adding variability that looks like a compound effect but is actually handling error.
• Sourcing on price alone. An unusually low price often reflects skipped independent testing, the exact verification that keeps the label consistent with what is actually in the vial.

Which GLP-1 peptide is right for your research

There is no single correct answer, because the three lead compounds occupy genuinely different positions in the evidence landscape: semaglutide the deepest trial record and post-marketing history, tirzepatide the strongest head-to-head evidence that a second receptor adds meaningful effect, and retatrutide the largest reported mean effect at the cost of being the least mature. Survodutide and cagrilintide sit further out on the frontier, with smaller published programs and, in cagrilintide's case, a fundamentally different receptor mechanism from the rest of the class.

A protocol organized around comparing mechanisms, rather than chasing the single largest headline number, is the version of this research that makes the most of what the class as a whole has to offer. The three compound-specific guides linked throughout this post go deep on each one: the complete retatrutide guide, the complete tirzepatide guide, and the complete semaglutide guide.

For research and educational purposes only. Not medical advice. Trial figures describe published clinical studies and, where noted, topline results reported ahead of full peer-reviewed publication; cross-compound comparisons are drawn from separate trials, not head-to-head studies, unless specifically identified as such (SURPASS-2). Semaglutide and tirzepatide are FDA-approved molecules under their respective brand names; retatrutide, survodutide, and cagrilintide are investigational and not approved for human use. Research-compound versions of any of these molecules discussed here for sourcing purposes are not intended for human use.